DRUG INDUSTRY

Addresses

Future Trends in Health Care: Charles M. West, 5767 [20MR]

Amendments

Research: development of orphan drugs (S. 1147), 20473, 20510 [25JY]

Analyses

Federal Food, Drug, and Cosmetic Act Amendment (S. 1520), 20960 [29JY]

Articles and editorials

Company Mourns Death of Abe Plough, 724 [22JA]

Dyes That Stain, 20878 [29JY]

How Not To Regulate, 20879 [29JY]

Lipstick You Can Live With, 20879 [29JY]

New Program Targets Health Care for Elderly, 10463 [3MY]

Shuttle Crystal Growth Tests Could Advance Cancer Research, 4591 [6MR]

Study Affirms Link Between Aspirin and Reye's Syndrome, 27188 [10OC]

Upjohn's Centennial Gift Is Extraordinary, 11157 [8MY]

Bills and resolutions

Aspirin: warning labels (see S. 538; H.R. 1381)

———warnings on certain drugs relative to Reye's syndrome (see H.R. 3640)

Cardiac drugs: extension of patents for certain (see S. 456)

Color additives: repeal provisional listing (see S. 1512; H.R. 3095)

Color dyes: ban use of certain (H. Res. 94), 9983 [1MY]

———terminate provisional listing of certain (see H.R. 2857)

Commissioner of Food and Drugs: appointment subject to Senate confirmation (see H.R. 3909)

Designer drugs: assessment by National Drug Enforcement Policy Board (see H.R. 2014)

Diet: prescription for drugs containing phenylpropanolamine (see H.R. 1673)

Drug Benefits Council: establish (see H.R. 168, 3311)

Exports: establish conditions (see S. 1770, 1848; H.R. 3995)

FDA: strengthen control over use of drugs and secure data on adverse reactions (see H.R. 1672)

Federal Food, Drug, and Cosmetic Act: amend (see S. 1520; H.R. 2177)

———remove prohibition relative to labeling and advertising (see H.R. 2244)

Food: define authority of Sec. of HHS to regulate food as drugs (see H.R. 2583)

———exemption from definition of drugs (see H.R. 1819)

Foreign trade: authorize export of certain unapproved drugs (see H.R. 3962)

Heroin: relief of terminal cancer patients (see H.R. 1597)

Investigators: limit compensation when using medical devices under certain exemption (see H.R. 3118)

Labeling: disclosure of active and inactive ingredients (see S. 1411)

Lasamid: duty (see S. 757)

L-ephedrine hydrochloride: rate of duty (see S. 1879)

Medicaid: optional program of pharmaceutical assistance (see H.R. 1542)

Medical care: availability of heroin for relief of terminal cancer patients (see H.R. 1597)

———extension of patents relative to cardiac drugs (see H.R. 1846)

Medicare: deny, revoke, or suspend registration to manufacture, distribute, or dispense a controlled substance by certain entities (see H.R. 1369)

National childhood vaccine-injury compensation program: establish (see H.R. 1780)

Orphan drug: amend Federal Food, Drug, and Cosmetic Act (see H.R. 2290)

Orphan drugs: amend Federal Food, Drug, and Cosmetic Act (see S. 1147)

Parenteral diacetylmorphine: availability for cancer patients (see S. 70)

Pharmacists: collective negotiations with third-party prepaid prescription program administrators and sponsors (see H.R. 2668)

Poland: reduced postal rates for certain parcels (see H.R. 1019)

Pregnancy: dissemination of information on effects and risks of drugs and devices on health of women (see H.R. 2685)

Sodium bicarbonate: rates of duty (see S. 1987; H.R. 4002)

Soviet Union: reduced postal rates for certain parcels (see H.R. 1019)

Vaccine-related injuries: compensation (see S. 827)

Eulogies

Abe Plough: Harry Danziger, 724 [22JA]

Letters

FDA user fees on drug certification applications: Margaret M. Heckler, Sec. of HHS, 27661 [16OC]

———Senators Hatch and Kennedy, 27661 [16OC]

FTC reporting requirement relative to predatory pricing: John M. Rector, 20453 [25JY]

Incomplete labeling of pharmaceuticals: Jeffrey L. Brown, 18351 [10JY]

Lists

Organizations supporting Orphan Drug Program, 27461 [15OC]

Memorials of legislature

Louisiana, 20937 [29JY]

Remarks in House

Color dyes: ban use of certain (H. Res. 94), 9984, 9989, 9990 [1MY]

Drug exports: establish conditions (H.R. 3995), 38724 [19DE], 38808, 38813 [20DE]

Emergency Reye's Syndrome Prevention Act: enact (H.R. 1381), 4257 [28FE]

FDA Approval Labeling Act: enact (H.R. 2244), 9556 [25AP], 16914 [24JN]

Foods Are Not Drugs Act: enact (H.R. 2583), 13346 [22MY]

Heart disease: extend patents on bretylium tosylate and bethanidine sulphate (H.R. 1846), 6867 [28MR]

Red and orange dyes: ban use of certain (H. Res. 94), 9983, 9984, 9989, 9990 [1MY]

Research: development of orphan drugs (S. 1147), Senate amendment, 21919 [31JY]

Remarks in Senate

Aged: pharmacy practice and geriatric patient program, 10463 [3MY]

Cardiac drugs: extension of patents for certain (S. 456), 2205 [7FE]

Children: labeling requirements on aspirin products (S. 538), 4037 [28FE]

Color additives: repeal provisional listing (S. 1512), 20877 [29JY]

Diseases: funding for the Orphan Drug Program, 27461-27463 [15OC]

———progress against tropical strains, 4746 [7MR]

Drugs: labeling requirements (S. 1411), 18350 [10JY]

Exports: establish conditions (S. 1770), 27964 [17OC]

———establish conditions (S. 1848), 31757-31761 [13NO]

FDA: congressional oversight of regulatory functions, 37559 [18DE]

———prohibit user fees on drug certification applications, 27661-27662 [16OC]

Federal Food, Drug, and Cosmetic Act: amend (S. 1520), 20958 [29JY]

Health: future trends in care provision, 5767 [20MR]

———link between aspirin and Reye's syndrome, 27187 [10OC]

L-ephedrine hydrochloride: rate of duty (S. 1879), 33400 [22NO]

National Association of Retail Druggists: tribute, 24702 [24SE]

Plough, Abe: tribute, 724 [22JA]

Research: development of orphan drugs (S. 1147), 13571 [23MY], 20471-20475 [25JY]

Schutte, H. Joseph: tribute, 33431 [22NO]

Sodium bicarbonate: rates of duty (S. 1987), 38582 [19DE]

Space shuttle: protein crystal growth experiments, 4591 [6MR]

Vaccine-related injuries: compensation (S. 827), 7030-7033 [2AP]

Reports

Establish Conditions for Export of Drugs: Committee on Labor and Human Resources (S. 1848) (S. Rept. 99-225), 37636 [18DE]

Injury Compensation Litigation: Lederle Co. (excerpt), 28179 [21OC]

Progress Against Tropical Diseases: Pharmaceutical Manufacturers Association, 4747-4748 [7MR]

Remove Prohibition on Labeling and Advertising Under Federal Food Drug and Cosmetic Act: Committee on Energy and Commerce (H.R. 2244) (H. Rept. 99-143), 13435 [23MY]

Statements

Loan Scholarship Program: National Association of Retail Druggists, 24702 [24SE]

Summaries

Establish Conditions for Drug Exports (H.R. 3995), 38808 [20DE]

Texts of

H.R. 1381, Emergency Reye's Syndrome Prevention Act, 4258 [28FE]

H.R. 1846, extend patents on bretylium tosylate and bethanidine sulphate, 6867 [28MR]

H.R. 2244, FDA Approval Labeling Act, 9556 [25AP], 16914 [24JN]

S. 456, extension of patents for certain cardiac drugs, 2205 [7FE]

S. 1147, amend the orphan drug provisions of the Federal Food, Drug, and Cosmetic Act, 16063 [18JN]